Skip to main content

Home

  • Home
  • Hot
  • New
  • Opinions
  • Media
    • The Times of Israel
    • The Yeshiva World
    • Voz Iz Neias
    • Matzav
  • Home
  • US to resume Johnson & Johnson vaccinations despite rare clot risk
23 Apr

US to resume Johnson & Johnson vaccinations despite rare clot risk

By admin 0 Comments

Scientific advisers decide vaccine's benefits outweigh risk after finding 15 cases of blood clots, 3 deaths out of nearly 8 million people given the shot

Details
Vote up!
Vote down!

Points: 1

Category: 
Israel & the Region
coronavirus vaccine
Johnson & Johnson
COVID-19
blood clots
AstraZeneca vaccine
  • Log in or register to post comments

Author

anon

admin

Hot

  • Third Yeshiva Student Dies Following Fiery Crash in Jackson, NJ
  • SHOCKING: Ex-Leader Of Hostages Forum: “They Only Work With Families With Anti-Bibi Views”
  • Trump Moves to Eliminate Federal Program Aimed at Bridging Digital Divide

User login

  • Create new account
  • Request new password

Recent comments

No comments available.